Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | STAMBP | O95630 | 1/20 | 0.43 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 4/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.42 |
| ▸ | BAD | Q92934 | 3/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28179640 | 0.81 | PKN1 (0.46) | PKN1PKN2PSMD14PARP1TRPV1 | |
| SCHEMBL30013145 | 0.81 | PKN1 (0.46) | PKN1PKN2PSMD14PARP1TRPV1 | |
| SCHEMBL31187611 | 0.80 | ALDH1A1 (0.47) | PARP1TRPV1 | |
| SCHEMBL666372 | 0.80 | ALDH1A1 (0.47) | PARP1TRPV1 | |
| SCHEMBL27949789 | 0.79 | PARP1 (0.40) | PKN1PKN2PARP1TRPV1 | |
| SCHEMBL8402853 | 0.79 | NPC1 (0.64) | PLK1PKN1PKN2NPC1CASP3 | |
| SCHEMBL29558330 | 0.79 | PARP1 (0.62) | PKN1PKN2PARP1FLT3PTK2 | |
| Hydrochloric Acid SCHEMBL11618161 | 0.79 | ALDH1A1 (0.46) | PARP1TRPV1 | |
| SCHEMBL528715 | 0.79 | PARP1 (0.62) | PKN1PKN2PARP1FLT3PTK2 | |
| SCHEMBL29829237 | 0.78 | PKN1 (0.46) | PKN1PKN2PARP1TRPV1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114786771-A | Quinazoline derivatives as inhibitors of LPA receptor 2 | 奇斯药制品公司 | 2022-07-22 | — | — | CN | claimed |
| CN-107223126-A | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | 多曼治疗学公司 | 2017-09-29 | — | — | CN | disclosed |
| US-8637532-B2 | Amino azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| EP-2598492-A1 | BICYCLIC AZAHETEROCYCLIC CARBOXAMIDES AS INHIBITORS OF THE KINASE P70S6K | Merck Patent GmbH (DE) | 2013-06-05 | — | — | EP | disclosed |
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| WO-2012013282-A1 | BICYCLIC AZAHETEROCYCLIC CARBOXAMIDES AS INHIBITORS OF THE KINASE P70S6K | MERCK PATENT GMBH (DE) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046269-A1 | Novel Amino Azaheterocyclic Carboxamides | AZI2, MKI67, MYC | PLK1 3614/4885PKN1 2936/4885PKN2 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.